Pasithea Therapeutics Corp. Common Stock (KTTA)

The neurofibromatosis type 1 market is expected to grow significantly due to advances in treatment, increased diagnoses, and ongoing clinical trials. Unmet needs in adult populations and systemic disease management create opportunities for new entrants and differentiated strategies.

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 100 points on Monday. The Dow traded up 0.26% to 36,341.44 while the NASDAQ rose 0.12% to 14,421.98. The S&P 500 also rose, gaining, 0.30% to 4,618.11. Check This Out: This Analyst With 84% Accuracy Rate Sees More Than 7% Upside In Broadcom - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts   Leading and Lagging Sectors   Industrials shares rose by 0.8% on Monday. In trading on Monday, communication services shares fell by 1.5%.   Top Headline   Macy's Inc (NYSE: M) shares jumped more than 20% on Monday following a report suggesting an investor group made a $5.8 billion buyout offer for the company.   Equities Trading UP   Pasithea Therapeutics Corp. (NASDAQ: KTTA) shares shot up 92% to $0.59 after the company announced preclinical results from two in vivo studies evaluating the antitumor efficacy of PAS-004 in NRAS mutation cancer xenograft models. Shares of ...

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week

Insider buying has these NASDAQ & NYSE penny stocks on the Robinhood watch list this week. The post 4 Cheap Robinhood Stocks To Buy According To Insiders In August 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.